AR099886A1 - Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación - Google Patents
Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparaciónInfo
- Publication number
- AR099886A1 AR099886A1 ARP150100942A ARP150100942A AR099886A1 AR 099886 A1 AR099886 A1 AR 099886A1 AR P150100942 A ARP150100942 A AR P150100942A AR P150100942 A ARP150100942 A AR P150100942A AR 099886 A1 AR099886 A1 AR 099886A1
- Authority
- AR
- Argentina
- Prior art keywords
- understanding
- taxane
- solid dispersion
- amorphes
- compressed
- Prior art date
Links
- 229940123237 Taxane Drugs 0.000 title abstract 3
- 239000007962 solid dispersion Substances 0.000 title abstract 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title abstract 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 229960001573 cabazitaxel Drugs 0.000 abstract 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 229950005692 larotaxel Drugs 0.000 abstract 1
- SEFGUGYLLVNFIJ-QDRLFVHASA-N larotaxel dihydrate Chemical compound O.O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@@]23[C@H]1[C@@]1(CO[C@@H]1C[C@@H]2C3)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 SEFGUGYLLVNFIJ-QDRLFVHASA-N 0.000 abstract 1
- BWKDAMBGCPRVPI-ZQRPHVBESA-N ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 abstract 1
- 229950001094 ortataxel Drugs 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 229950008882 polysorbate Drugs 0.000 abstract 1
- 229920000136 polysorbate Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- MODVSQKJJIBWPZ-VLLPJHQWSA-N tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 abstract 1
- 229950009016 tesetaxel Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Una dispersión sólida amorfa que comprende un taxano o una de sus sales aceptables desde el punto de vista farmacéutico polivinilpirrolidona, polisorbato, y lauril sulfato de sodio. Reivindicación 2: La dispersión sólida amorfa de la reivindicación 1, en donde el taxano es cualquiera seleccionado del grupo que consiste en paclitaxel, docetaxel, cabazitaxel, larotaxel, ortataxel, tesetaxel, y una combinación de los anteriores.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2014/002734 WO2015152433A1 (en) | 2014-03-31 | 2014-03-31 | Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099886A1 true AR099886A1 (es) | 2016-08-24 |
Family
ID=54240734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100942A AR099886A1 (es) | 2014-03-31 | 2015-03-30 | Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9867801B2 (es) |
| EP (1) | EP3125872B1 (es) |
| JP (1) | JP6539675B2 (es) |
| KR (1) | KR101851571B1 (es) |
| CN (1) | CN106255496B (es) |
| AR (1) | AR099886A1 (es) |
| AU (1) | AU2015242738B2 (es) |
| BR (1) | BR112016022528B1 (es) |
| CA (1) | CA2944438C (es) |
| CL (1) | CL2016002441A1 (es) |
| CU (1) | CU24486B1 (es) |
| DK (1) | DK3125872T3 (es) |
| DO (1) | DOP2016000262A (es) |
| ES (1) | ES2748686T3 (es) |
| GT (1) | GT201600208A (es) |
| HU (1) | HUE046616T2 (es) |
| IL (1) | IL247977B (es) |
| LT (1) | LT3125872T (es) |
| MA (1) | MA39361B1 (es) |
| MX (1) | MX373189B (es) |
| MY (1) | MY175387A (es) |
| PE (1) | PE20161477A1 (es) |
| PH (1) | PH12016501825B1 (es) |
| PL (1) | PL3125872T3 (es) |
| PT (1) | PT3125872T (es) |
| RU (1) | RU2684632C2 (es) |
| SA (1) | SA516371952B1 (es) |
| SG (1) | SG11201607456RA (es) |
| SI (1) | SI3125872T1 (es) |
| TW (1) | TWI706793B (es) |
| UA (1) | UA117610C2 (es) |
| UY (1) | UY36055A (es) |
| WO (2) | WO2015152433A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3380079A4 (en) * | 2015-11-25 | 2019-08-21 | Patheon Development Services Inc. | AMORPHOUS DISPERSION GRANULES AND PHARMACEUTICAL FORMS FOR ORAL USE |
| MA44987A (fr) * | 2016-05-09 | 2019-03-20 | Dispersol Technologies Llc | Formulations de médicaments améliorées |
| CN110742895A (zh) * | 2017-03-30 | 2020-02-04 | 复旦大学附属中山医院 | Fxr激动剂在制备治疗脂肪肉瘤药物中的用途 |
| TWI833710B (zh) * | 2017-10-06 | 2024-03-01 | 香港商慧源香港創新有限公司 | 高單位含量口服型紫杉烷組合物及方法 |
| WO2019094688A1 (en) * | 2017-11-10 | 2019-05-16 | Dispersol Technologies, Llc | Improved drug formulations |
| TWI849043B (zh) * | 2019-01-25 | 2024-07-21 | 英屬開曼群島商百濟神州有限公司 | B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途 |
| CN109851593B (zh) * | 2019-02-01 | 2021-04-16 | 沈阳药科大学 | 基于淋巴介导转运的甘油三酯前药及其制备方法 |
| CN110105368B (zh) * | 2019-05-09 | 2022-01-07 | 上海大学 | 去氧紫杉烷类似物及其制备方法 |
| IL320609A (en) * | 2019-08-26 | 2025-07-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| JP7731883B2 (ja) * | 2019-12-02 | 2025-09-01 | アストラゼネカ・アクチエボラーグ | ６－（２－クロロ－６－メチルピリジン－４－イル）－５－（４－フルオロフェニル）－１，２，４－トリアジン－３－アミンの固形製剤処方物 |
| WO2021177930A1 (en) * | 2020-03-06 | 2021-09-10 | Vyshnevskyy Ihor Anatoliyovych | Pharmaceutical composition with increased solubility of gesperidine and method of its preparation |
| EP4225747A1 (en) | 2020-10-07 | 2023-08-16 | Athenex, Inc. | Acetamido-phenyltetrazole derivatives and methods of using the same |
| WO2022271765A1 (en) * | 2021-06-23 | 2022-12-29 | Blueprint Medicines Corporation | Pharmaceutical compositions of an epidermal growth factor receptor inhibitor |
| EP4479092A1 (en) * | 2022-02-14 | 2024-12-25 | Purdue Research Foundation | Polymer salts for improved drug delivery from amorphous solid dispersions |
| KR20240151747A (ko) * | 2022-03-08 | 2024-10-18 | (주)씨앤팜 | 도세탁셀 또는 이의 약학적으로 허용 가능한 염을 포함하는 약학적 조성물 및 이의 제조방법 |
| CN115429766B (zh) * | 2022-09-08 | 2023-10-27 | 江苏集萃新型药物制剂技术研究所有限公司 | 淫羊藿苷固体分散体、复方药物双层片剂及其制备方法与应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU230338B1 (hu) | 1997-06-27 | 2016-02-29 | Abraxis Bioscience Llc | Gyógyászati hatóanyagokat tartalmazó új készítmények, eljárás ilyen készítmények előállítására és alkalmazására |
| US6610317B2 (en) | 1999-05-27 | 2003-08-26 | Acusphere, Inc. | Porous paclitaxel matrices and methods of manufacture thereof |
| KR20030041577A (ko) * | 2001-11-20 | 2003-05-27 | 디디에스텍주식회사 | 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물 |
| CA2540104A1 (en) * | 2003-09-30 | 2005-04-07 | Solubest Ltd. | Water soluble nanoparticles comprising inclusion complexes |
| AU2005297923B2 (en) * | 2004-10-25 | 2010-12-23 | Japan Tobacco Inc. | Solid medicinal preparation improved in solubility and stability and process for producing the same |
| CN1840196A (zh) * | 2006-01-27 | 2006-10-04 | 无锡杰西医药科技有限公司 | 一种适用于难溶性药物的分散剂 |
| WO2007073389A1 (en) * | 2005-12-22 | 2007-06-28 | Teva Pharmaceutical Industries Ltd. | Compressed solid dosage forms with drugs of low solubility and process for making the same |
| US9833510B2 (en) * | 2007-06-12 | 2017-12-05 | Johnson & Johnson Consumer Inc. | Modified release solid or semi-solid dosage forms |
| EP2190413B1 (en) * | 2007-08-24 | 2015-01-28 | Stichting Het Nederlands Kanker Instituut | Compositions for the treatment of neoplastic diseases |
| US9089544B2 (en) * | 2007-08-24 | 2015-07-28 | Slotervaart Participaties Bv | Composition |
| GB0716591D0 (en) | 2007-08-24 | 2007-10-03 | Vereniging Het Nl Kanker I | Composition |
| MX2010008138A (es) * | 2008-01-25 | 2010-08-10 | Gruenenthal Gmbh | Forma de dosis farmaceutica. |
| CN101632630A (zh) * | 2008-07-24 | 2010-01-27 | 北京诺美医药科技有限公司 | 一种普罗布考固体分散体 |
| JP2012500788A (ja) * | 2008-08-22 | 2012-01-12 | スティヒティング ヘット ネーデルランド カンケル インスティテュート | 組成物 |
| JP5751868B2 (ja) * | 2010-03-30 | 2015-07-22 | 日東電工株式会社 | フィルム状製剤及びその製造方法 |
| KR20130109092A (ko) * | 2010-06-09 | 2013-10-07 | 아보트 러보러터리즈 | 키나제 억제제를 함유하는 고체 분산물 |
| ES2524408T5 (es) * | 2010-11-19 | 2022-04-25 | Gilead Sciences Inc | Composiciones terapéuticas que comprenden rilpivirina HCl y tenofovir disoproxil fumarato |
| US20150011525A1 (en) * | 2011-09-13 | 2015-01-08 | Isp Investments Inc. | Solid dispersion of poorly soluble compounds comprising crospovidone and at least one water-soluble polymer |
| CN102357075A (zh) * | 2011-09-30 | 2012-02-22 | 武汉平华生物医药科技有限公司 | 一种多西他赛纳米制剂及其制备方法 |
-
2014
- 2014-03-31 WO PCT/KR2014/002734 patent/WO2015152433A1/en not_active Ceased
-
2015
- 2015-03-20 ES ES15773354T patent/ES2748686T3/es active Active
- 2015-03-20 DK DK15773354.4T patent/DK3125872T3/da active
- 2015-03-20 PL PL15773354T patent/PL3125872T3/pl unknown
- 2015-03-20 CN CN201580016355.2A patent/CN106255496B/zh active Active
- 2015-03-20 RU RU2016136636A patent/RU2684632C2/ru active
- 2015-03-20 US US15/300,515 patent/US9867801B2/en active Active
- 2015-03-20 BR BR112016022528-7A patent/BR112016022528B1/pt not_active IP Right Cessation
- 2015-03-20 EP EP15773354.4A patent/EP3125872B1/en active Active
- 2015-03-20 CA CA2944438A patent/CA2944438C/en active Active
- 2015-03-20 PE PE2016001849A patent/PE20161477A1/es unknown
- 2015-03-20 MX MX2016012596A patent/MX373189B/es active IP Right Grant
- 2015-03-20 JP JP2016559161A patent/JP6539675B2/ja active Active
- 2015-03-20 SG SG11201607456RA patent/SG11201607456RA/en unknown
- 2015-03-20 MA MA39361A patent/MA39361B1/fr unknown
- 2015-03-20 UA UAA201609267A patent/UA117610C2/uk unknown
- 2015-03-20 WO PCT/KR2015/002756 patent/WO2015152544A1/en not_active Ceased
- 2015-03-20 MY MYPI2016001721A patent/MY175387A/en unknown
- 2015-03-20 LT LTEP15773354.4T patent/LT3125872T/lt unknown
- 2015-03-20 AU AU2015242738A patent/AU2015242738B2/en active Active
- 2015-03-20 KR KR1020167027373A patent/KR101851571B1/ko active Active
- 2015-03-20 CU CU2016000144A patent/CU24486B1/es unknown
- 2015-03-20 PT PT157733544T patent/PT3125872T/pt unknown
- 2015-03-20 HU HUE15773354A patent/HUE046616T2/hu unknown
- 2015-03-20 SI SI201530891T patent/SI3125872T1/sl unknown
- 2015-03-27 UY UY0001036055A patent/UY36055A/es not_active Application Discontinuation
- 2015-03-30 AR ARP150100942A patent/AR099886A1/es unknown
- 2015-03-30 TW TW104110283A patent/TWI706793B/zh active
-
2016
- 2016-09-19 PH PH12016501825A patent/PH12016501825B1/en unknown
- 2016-09-22 IL IL247977A patent/IL247977B/en active IP Right Grant
- 2016-09-27 DO DO2016000262A patent/DOP2016000262A/es unknown
- 2016-09-28 CL CL2016002441A patent/CL2016002441A1/es unknown
- 2016-09-29 SA SA516371952A patent/SA516371952B1/ar unknown
- 2016-09-30 GT GT201600208A patent/GT201600208A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR099886A1 (es) | Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación | |
| EP3501009A4 (en) | DYNAMIC SORTING OF MATRIX OPERATIONS | |
| EP3592944A4 (en) | Dynamic artificial lift | |
| CL2016001963A1 (es) | Heteroarilos inhibidores de syk | |
| CL2017003240A1 (es) | Anticuerpos anti-rnf43 novedosos y métodos para su uso | |
| EP3500993A4 (en) | DYNAMIC ALIASING OF CYCLOTHING | |
| MX2016012124A (es) | Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos. | |
| EP3400472A4 (en) | DYNAMIC FRESNEL PROJECTOR | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| CL2016002495A1 (es) | Derivados de piridina macrocíclicos . | |
| GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
| CR20160438A (es) | Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación | |
| EA201790627A1 (ru) | СТИМУЛЯТОРЫ рГЦ | |
| ITUA20162445A1 (it) | Dispositivo di prelievo di articoli. | |
| DOP2017000073A (es) | Nuevos activadores de la guanilato ciclasa soluble y su uso | |
| EP3567894A4 (en) | BEAM FORMATION LEARNING | |
| EP3604866A4 (en) | PISTON RING | |
| EP3583943A4 (en) | PHARMACEUTICAL COMPOSITION | |
| EP3476864A4 (en) | ANTIBODIES AGAINST ETAR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| EP3459369A4 (en) | PHARMACEUTICAL COMPOSITION WITH LACTOBACILLUS SP. KCCM 11826P STRAIN FOR PREVENTING HYPERPHOSPHATMA AND TREATING CHRONIC KIDNEY DISEASE AND HEALTH FUNCTIONAL FOOD | |
| ES1159036Y (es) | Máquina lanza balones. | |
| EP4290101C0 (de) | Kolbenring | |
| EP3646867C0 (en) | PHARMACEUTICAL COMPOSITION | |
| DK4056557T3 (da) | Benzazepinderivater nyttige som medikamenter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |